Intimation of the approval of the audited consolidated financial statements for the year ended March 31, 2025, under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations )
SYRMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts less than Nifty Smallcap 250 and 1.2 pts less than its Industrial Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Syrma SGS Technology approved its audited consolidated financial statements for FY25 (year ended March 31, 2025), pending shareholder approval at the upcoming AGM. Consolidated revenue from operations grew about 20% YoY to ₹37,866.91 million from ₹31,541.17 million, while profit after tax jumped roughly 48% to ₹1,844.50 million from ₹1,243.40 million. Profit before tax rose to ₹2,370.75 million (vs ₹1,664.41 million), with basic EPS climbing to ₹9.55 from ₹6.06. Total assets stood at ₹42,046.71 million. Net cash from operating activities was positive at ₹1,764.63 million, a strong turnaround from a ₹1,091.31 million outflow in FY24. The auditor, Walker Chandiok & Co LLP (newly appointed, replacing predecessor Deloitte Haskins & Sells LLP), issued an unmodified (clean) opinion, though it flagged revenue recognition and goodwill impairment (₹3,221 million on books, with ₹2,039 million at the Johari Medtech unit) as key audit matters requiring close attention. Exceptional items of ₹21.38 million were reported during the year.
Strong double-digit revenue and nearly 50% PAT growth signal solid operational momentum and margin improvement, likely positive for the stock. Investors should monitor the large goodwill balance and the change of statutory auditor as items to track going forward.